LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.37 USD | +1.33% |
|
+1.87% | -22.94% |
| May. 15 | Legend Expects to Log Profit in 2026 | MT |
| May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 538M | Sales 2025 * | 1.06B | Capitalization | 8.45B |
|---|---|---|---|---|---|
| Net income 2024 * | -313M | Net income 2025 * | -129M | EV / Sales 2024 * | 14.5 x |
| Net cash position 2024 * | 648M | Net cash position 2025 * | 787M | EV / Sales 2025 * | 7.23 x |
| P/E ratio 2024 * |
-47.4
x | P/E ratio 2025 * |
-103
x | Employees | 2,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | +1.33% | ||
| 1 week | +1.87% | ||
| Current month | +6.01% | ||
| 1 month | -7.48% | ||
| 3 months | -20.20% | ||
| 6 months | -27.07% | ||
| Current year | -22.94% |
1 week
42.11
46.89
1 month
42.0848.97
Current year
42.0870.13
1 year
42.0877.32
3 years
30.7677.32
5 years
23.4177.32
10 years
23.4177.32
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 19-08-31 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Corazon Sanders
BRD | Director/Board Member | 67 | 20-04-30 |
Li Zhu
BRD | Director/Board Member | 74 | 20-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 2 M€ | -12.32% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 46.37 | +1.33% | 1,049,636 |
| 24-05-15 | 45.76 | +3.11% | 1,052,434 |
| 24-05-14 | 44.38 | +3.28% | 1,110,387 |
| 24-05-13 | 42.97 | -0.62% | 1,328,091 |
| 24-05-10 | 43.24 | -5.01% | 887,591 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
46.37
USD
Average target price
85.2
USD
Spread / Average Target
+83.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.94% | 8.45B | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| -11.90% | 22.41B | |
| +0.23% | 22.28B | |
| -5.66% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- LEGN Stock
